Kano

The trial investigates the safety, tolerability, effectiveness, and how the body processes and responds to osivelotor in people with sickle cell disease (SCD). This Phase 2/3, multicenter study involves adults and adolescents with SCD, aiming to find the best dose and compare osivelotor to a placebo. The study also includes a long-term extension to assess ongoing safety and blood-related effects. Osivelotor is given orally as tablets. The study has three parts: Part A focuses on determining a safe and effective dose in adults; Part B compares osivelotor to placebo in adults and adolescents over 48 weeks; and the Open Label Extension (OLE) offers continued treatment to those who completed Part B to monitor long-term safety and responses. Participants will be monitored throughout the study periods with assessments of safety, tolerability, and treatment effects. These include evaluations at 12 weeks (Part A), 48 weeks (Part B), and approximately 24 months after the last participant joins (OLE). Researchers will track blood values, side effects, and disease-related events to understand how the drug works and its impact on SCD over time.

Researchers are evaluating the long-term safety and effectiveness of etavopivat, a new oral medicine being developed to treat inherited blood disorders such as sickle cell disease and thalassemia. These disorders affect hemoglobin, the protein responsible for carrying oxygen in the body. This phase 3 study aims to monitor how well etavopivat works and its safety profile over an extended period. Participants will receive one of three forms of etavopivat (A, B, or C) as oral doses. The study is open-label and multicenter, involving adults, adolescents, and children who have previously completed treatment in an etavopivat parent study and continue to benefit clinically. The treatment period can last up to 264 weeks but may end earlier if etavopivat is approved in the participant's country. During the study, researchers will track the number of treatment-emergent adverse events and adverse reactions for each participant by indication and age group from baseline through the end of the study, which can last up to 316 weeks. Participants' safety and response to long-term treatment will be closely monitored throughout this period.

Researchers are evaluating how well Nigeria's National Sodium Reduction Program, led by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC), is being implemented. This program uses the WHO's SHAKE package, which includes strategies like monitoring salt intake, working with industry, adopting labeling standards, educating consumers, and promoting healthy eating environments. The aim is to reduce sodium intake across the population to help prevent and control high blood pressure. The study involves repeated assessments at three time points: baseline (Wave 1), 18 months later (Wave 2), and 36 months later (Wave 3). It uses a type III hybrid, mixed method design, including stakeholder interviews, population surveys, and retail food surveys. The retail surveys capture data on packaged and unpackaged foods as well as informal restaurants using the FoodSwitch program. Researchers apply implementation science frameworks to guide and evaluate the program's reach, effectiveness, adoption, and sustainability. Participants will be assessed through surveys and interviews over the study period. Researchers will measure changes in average population sodium intake, including 24-hour urinary sodium, from baseline to follow-up waves. They will also study dietary sources of sodium at baseline and at 36 months. The study includes monitoring the acceptability, feasibility, and fidelity of the program, along with contextual factors influencing success. Participation is expected to last over three years, with multiple waves of data collection and ongoing evaluation.

Researchers are evaluating a multimedia social and behavior change intervention in Kano and Kaduna states, Nigeria, to study its impact on family planning and reproductive decisions among women and couples. This study aims to assess the intervention's effectiveness, cost-efficiency, and sustainability over three years (2025-2028) using a mixed-methods, prospective longitudinal cohort design. The intervention targets low modern contraceptive use, which remains a challenge in Nigeria, especially in Kano and Kaduna, compared to the national average. The intervention, led by BBC Media Action in collaboration with partners, uses multiple media channels including TV drama, radio shows, public service announcements, social media, mobile interactive voice response drama, and community engagement activities. Additionally, family planning services supported by Marie Stopes International provide supply-side measures like provider training and commodity supply to improve service quality. The evaluation includes comparison with Nasarawa state, which does not receive the intervention. Participants will be women aged 15 to 44 years residing in the selected areas, surveyed at baseline before the intervention and followed up two years after implementation begins. Assessments include surveys on current family planning use, intent to use methods, and attitudes towards family planning. Qualitative interviews with women, their partners, program implementers, and key stakeholders will explore behavioral pathways and sustainability. Cost data will be collected to analyze cost efficiency. The study monitors the intervention's impact and supports evidence for family planning and mass media behavior change programs.

Access to safe water is a major health challenge in Nigeria, where most people lack access to safely managed drinking water. Waterborne diseases cause many child deaths each year. This research evaluates a community-based program that distributes chlorine to treat water at home. The goal is to see how well this program improves water safety and knowledge about safe water practices in Kano State over six months. The study involves 30 communities divided into three groups. Twenty communities will receive community demonstrations where local leaders and health staff introduce the chlorine product WaterGuard+. Eligible women will learn how to use it and receive a bottle and some money. At least one chlorine redemption point will be set up in each community where households can get monthly supplies of the chlorine product. Five control communities will later receive a voucher program and sensitization, while five will remain without intervention. Participants will be monitored for six months to see if they treat their drinking water with chlorine. Researchers will test water samples for chlorine and contamination, and assess knowledge of safe water use. Redemption logs will track chlorine distribution. The study aims to provide evidence on cost-effective ways to expand safe water access in low-resource areas, informing broader strategies in sub-Saharan Africa.

This research aims to collect real world data on patient characteristics, disease management, healthcare use, and outcomes for people living with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding how these conditions are managed and the quality of care patients receive in everyday clinical practice across many countries. The registry is observational and voluntary, designed to fill gaps in knowledge about these diseases globally. The study uses a multinational, observational registry with a cloud-based electronic case report form (eCRF) to gather both prospective and retrospective data. This system is accessible to doctors managing patients with type 2 diabetes, hypertension, heart failure, or chronic kidney disease worldwide. There are no specific treatments or interventions given as part of this study since it is a data collection registry. Participants provide information for an average of 3 years during the study. Researchers will collect data on patient characteristics, disease management, healthcare use, quality of care indicators, cardiovascular outcomes, kidney outcomes, and other related complications. The registry allows ongoing data entry and monitoring to better understand real world outcomes and care quality for these conditions.

Researchers are evaluating a management program for pregnant women with Hypertensive Disorders of Pregnancy (HDP) at four health institutions in Abuja and Kano, Nigeria. The study aims to develop and test a specialized package to help improve blood pressure control and overall cardiovascular health in these patients after delivery. It focuses on whether a home blood pressure monitoring program tailored to the Nigerian context can lead to better blood pressure outcomes postpartum. The program being studied is called the HDP Implementation Bundle and includes four main parts: patient education, home blood pressure monitoring, a customized follow-up plan after delivery, and providing free or discounted blood pressure medications when needed. This bundle will be applied at the four participating hospitals to create a supportive home blood pressure monitoring system for postpartum patients with HDP. Participants will be monitored for changes in their blood pressure from the start of the study to six weeks after delivery. The study will assess how well the program is accepted, how closely it is followed, and its effectiveness in controlling blood pressure. Patients' blood pressure readings, adherence to treatment, and cardiovascular health will be tracked during this time to evaluate the program's impact.

Researchers are evaluating two combination interventions designed to address HIV among youth aged 15 to 24 in Nigeria. These interventions include mHealth and Peer Navigation components, focusing on identifying youth living with HIV, linking them to care, promoting pre-exposure prophylaxis (PrEP) uptake among those testing negative, and supporting adherence to antiretroviral therapy (ART) for newly diagnosed individuals. The study involves two parallel 48-week trials conducted in six Nigerian states, aiming to assess both the effectiveness and implementation success of these approaches. The first intervention, HIV Case Finding, targets young men, especially young men who have sex with men (YMSM), to encourage HIV testing and linkage to care if positive, and PrEP initiation if negative. This is a single-arm trial enrolling 6000 participants. The second, HIV Treatment Intervention, is a randomized controlled trial enrolling 600 youth newly diagnosed with HIV who are starting ART for the first time. Interventions include behavioral supports such as peer navigation, motivational interviewing, social media outreach, and SMS reminders alongside standard care. Participants will be involved for 48 weeks, during which they will receive support to promote HIV testing, linkage to care, PrEP uptake, and ART adherence. Researchers will monitor viral suppression and adherence to ART in the treatment group and assess identification of HIV-positive youth and linkage to care in the case finding group. The study will also evaluate the success of intervention implementation in the target populations. Regular follow-up and support through peer navigators and digital messaging are part of the participant experience throughout the study period.

Researchers are evaluating the effects of pre-operative chlorhexidine mouthwash and perioperative oxygen levels on the rates of pneumonia and surgical site infections in patients undergoing major abdominal surgery. This Phase 3, multi-center, randomized controlled trial is conducted across hospitals in low and middle-income countries, focusing on adults and children aged 10 years or older having elective or emergency midline laparotomy. The study aims to reduce serious postoperative complications that significantly contribute to mortality and healthcare burden, especially in these resource-limited settings. Participants will be randomly assigned to one of four groups combining the use or non-use of chlorhexidine mouthwash before surgery and different oxygen concentrations during surgery: (a) mouthwash with high oxygen (80-100% FiO2), (b) no mouthwash with high oxygen, (c) mouthwash with low oxygen (21-30% FiO2), or (d) no mouthwash with low oxygen. The trial includes a 6-month internal pilot phase to assess recruitment and compliance, followed by a main phase enrolling approximately 12,924 participants. During the study, researchers will monitor participants for pneumonia and surgical site infections within 30 days after surgery using CDC definitions. Data on treatment adherence and participant outcomes will be collected and assessed by blinded outcome assessors. The study will track complications and follow patients through their recovery to evaluate how these interventions might reduce postoperative infections and improve surgical outcomes.

Researchers are conducting a Phase 3, double-blinded, placebo-controlled, multicenter trial to assess whether azithromycin taken as a preventive treatment can reduce death rates in adults with advanced HIV disease. Participants eligible for the study must have confirmed HIV infection with low CD4 counts or specific treatment histories, reflecting advanced immunosuppression. The trial aims to better understand mortality outcomes related to this preventive approach in this population. Participants will be randomly assigned to receive either azithromycin tablets or placebo tablets for 28 days. All participants will be followed for 24 weeks after randomization to measure the main outcome of death from any cause, with total follow-up lasting 48 weeks. The study compares the effects of azithromycin prophylaxis against an inactive placebo to evaluate its impact on survival. During the study, participants will be monitored regularly to track health outcomes, particularly mortality. They must be able to start or adjust antiretroviral therapy within four weeks of joining the trial. Researchers will closely observe for any adverse effects, treatment adherence, and overall health status throughout the follow-up period to assess the safety and effectiveness of the intervention.